Insulin Pump Tandem denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for insulin pump tandem are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Insulin Pump Tandem
## Why Cigna Issues a Duplicate-Therapy Denial for a Tandem Insulin Pump
A duplicate-therapy denial for a Tandem insulin pump typically arises when Cigna's claims system identifies that the patient already has an active or recently approved claim for the same or a similar device — for example, an older insulin pump that is still within its coverage warranty period, or a concurrent claim for a different pump or infusion device. The insurer treats the new claim as duplicative of an existing benefit already in force.
This denial does not necessarily mean the new pump is clinically inappropriate. It means Cigna's system flagged an apparent overlap in device coverage, and the claim was denied without a clinical review of whether the new device is actually needed to replace or upgrade the existing one.
## Why This Denial Is Appealable
Duplicate-therapy denials are frequently reversed when the clinical record establishes that the new device is not truly duplicative — for example, because the existing device has malfunctioned, reached end of life, or no longer meets the patient's clinical needs:
- Internal appeal (ACA §2719 / ERISA §503): Submit a full-and-fair internal appeal. Include documentation showing why the new device is not duplicative of an existing benefit.
- External review: After the internal process, request independent external review under ACA §2719. The external reviewer's decision is binding on Cigna. The external-review window is generally within four months of the final internal denial.
- Expedited review: Available if the patient's diabetes management is actively at risk due to a failed or non-functional pump.
## Documentation to Gather
1. Existing device status: Records showing the current status of any prior pump — including age, malfunction history, repair records, and a prescriber statement that the existing device no longer meets the patient's needs. 2. Clinical rationale for the new device: A prescriber letter explaining what is clinically distinct about the Tandem device (such as integration with a continuous glucose monitor or closed-loop control features) and why the new capabilities are medically necessary for this patient. 3. Diabetes management history: Chart notes documenting glycemic control history, hypoglycemic episodes, and the clinical context that makes the new device necessary. 4. Replacement vs. upgrade distinction: If this is a replacement for a failed device, document the failure. If this is an upgrade driven by clinical need, document the clinical inadequacy of the existing device. 5. Prescriber medical-necessity letter: Addressed specifically to the duplicate-therapy finding, explaining why coverage of the Tandem pump does not constitute a duplicate benefit.
## Criteria-Mapping Structure
Obtain Cigna's current published medical policy for insulin infusion pumps and address the duplicate-therapy criteria directly:
| Cigna Duplicate-Therapy Basis | Rebuttal Evidence | |---|---| | [State the specific duplicate criterion or existing-device finding from the denial] | [Device status, clinical justification, and prescriber attestation] |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →